Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP ‐mutated keratinocytes
Experimental Dermatology · 2024
DOI: 10.1111/exd.15046 ↗At a glance
Journal article in Experimental Dermatology, 2024. Written by Daniela Andrei and 9 co-authors. Institution: Department of Dermatology, Expertise Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Net…. Major MEDLINE topics: Desmoplakins, ErbB Receptors, Hair Diseases, Keratoderma, Palmoplantar. Cited 2 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Stichting Vlinderkind.
Abstract (original language)
Desmoplakin (DSP) is a desmosomal component expressed in skin and heart, essential for desmosome stability and intermediate filament connection. Pathogenic variants in the DSP gene encoding DSP, lead to heterogeneous skin, adnexa and heart‐related phenotypes, including skin fragility, woolly hair (WH), palmoplantar keratoderma (PPK) and arrhythmogenic/dilated cardiomyopathy (ACM/DCM). The ambiguity of computer‐based prediction analysis of pathogenicity and effect of DSP variants, indicates a necessity for functional analysis. Here, we report a heterozygous DSP variant that was not previously described, NM_004415.4:c.3337C>T (NM_004415.4(NP_004406.2):p.(Arg1113*)) in a patient with PPK, WH and ACM. RNA and protein analysis revealed ~50% reduction of DSP mRNA and protein expression. Patient's keratinocytes showed fragile cell–cell connections and perinuclear retracted intermediate filaments. Epidermal growth factor receptor (EGFR) is a transmembrane protein expressed in the basal epidermal layer involved in proliferation and differentiation, processes that are disrupted in the development of PPK, and in the regulation of the desmosome. In skin of the abovementioned patient, evident EGFR upregulation was observed. EGFR inhibition in patient's keratinocytes strongly increased DSP expression at the plasma membrane, improved intermediate filament connection with the membrane edges and reduced the cell–cell fragility. This cell phenotypic recovery was due to a translocation of DSP to the plasma membrane together with an increased number of desmosomes. These results indicate a therapeutic potential of EGFR inhibitors for disorders caused by DSP haploinsufficiency.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Expertise Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Genetics, Expertise Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
ORCID profiles: Daniela Andrei, Jeroen Bremer, Mathilde C S C Vermeer
Funding
- Stichting Vlinderkind
Cite
APA
Andrei, D., Bremer, J., Kramer, D., Nijenhuis, A. M., van der Molen, M., Diercks, G. F. H., van den Akker, P. C., Vermeer, M. C. S. C., van der Meer, P., & Bolling, M. C. (2024). Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP ‐mutated keratinocytes. Experimental Dermatology. https://doi.org/10.1111/exd.15046
Vancouver
Andrei D, Bremer J, Kramer D, Nijenhuis AM, van der Molen M, Diercks GFH, et al. Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP ‐mutated keratinocytes. Experimental Dermatology. 2024. doi:10.1111/exd.15046
BibTeX
@article{Andrei2024,
author = {Andrei, Daniela and Bremer, Jeroen and Kramer, Duco and Nijenhuis, Albertine M and van der Molen, Marije and Diercks, Gilles F H and van den Akker, Peter C and Vermeer, Mathilde C S C and van der Meer, Peter and Bolling, Maria C},
title = {Epidermal growth factor receptor inhibition leads to cellular phenotype correction of DSP ‐mutated keratinocytes},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15046}
}
EUVIMED